Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 5/20 | 0.98 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.98 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.98 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.98 |
| ▸ | PLG | P00747 | 4/20 | 0.75 |
| ▸ | PLAU | P00749 | 1/20 | 0.75 |
| ▸ | F11 | P03951 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326662 | 0.99 | KLKB1 (1.00) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL26628958 | 0.97 | KLKB1 (0.96) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL14159641 | 0.85 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL19988160 | 0.85 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL19988159 | 0.85 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL14159640 | 0.85 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL10425157 | 0.84 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| Hydrochloric Acid SCHEMBL10425156 | 0.84 | KLKB1 (0.72) | KLKB1PRSS1PRSS2PRSS3PLG | |
| SCHEMBL7066980 | 0.84 | KLKB1 (0.73) | KLKB1PRSS1PRSS2PRSS3PLG | |
| SCHEMBL7066988 | 0.84 | KLKB1 (0.73) | KLKB1PRSS1PRSS2PRSS3PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590068-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388548-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388549-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388545-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20220204454-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-06-30 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4010320-A1 | PROCESS-SCALE SYNTHESIS OF A PLASMA KALLIKREIN INHIBITOR | Biocryst Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
| CN-114206839-A | Production-scale synthesis of plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220041571-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | DRI UK LP (KY) | 2022-02-10 | — | — | US | disclosed |
| US-11234939-B2 | Dosage forms comprising a plasma kallikrein inhibitor | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11230537-B2 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 9/4885PRSS2 15/4885 |
| US-20220204454-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK5 | KLKB1 1/4885PRSS1 40/4885PRSS2 47/4885 |
| US-20220041571-A1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF | CYP3A4, CYP4B1, TPMT | KLKB1 4305/4885PRSS1 2974/4885PRSS2 3633/4885 |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 9/4885PRSS2 17/4885 |
| US-20250388545-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 12/4885PRSS2 17/4885 |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 9/4885PRSS2 17/4885 |
| US-20250388549-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 7/4885PRSS2 13/4885 |
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK2, KLK1 | KLKB1 1/4885PRSS1 9/4885PRSS2 15/4885 |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, F2, KLK1 | KLKB1 1/4885PRSS1 9/4885PRSS2 18/4885 |
| US-20250388548-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 11/4885PRSS2 16/4885 |
| US-11230537-B2 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885PRSS1 57/4885PRSS2 126/4885 |
| US-12590068-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 7/4885PRSS2 13/4885 |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885PRSS1 41/4885PRSS2 103/4885 |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885PRSS1 11/4885PRSS2 16/4885 |
| US-11234939-B2 | Dosage forms comprising a plasma kallikrein inhibitor | KLKB1, KLK1, KLK5 | KLKB1 1/4885PRSS1 34/4885PRSS2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.